{"id":"pegol-sihematide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201831","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"It works by mimicking the action of endogenous erythropoietin, which binds to the erythropoietin receptor on bone marrow cells, stimulating the differentiation and proliferation of red blood cell precursors.","oneSentence":"Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:49.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease (CKD)"}]},"trialDetails":[{"nctId":"NCT03902691","phase":"PHASE3","title":"Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2019-05-15","conditions":"Chronic Kidney Diseases","enrollment":372},{"nctId":"NCT03903809","phase":"PHASE3","title":"Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2019-06-20","conditions":"Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":175},{"nctId":"NCT02619097","phase":"PHASE1","title":"Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-06","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":24},{"nctId":"NCT02586402","phase":"PHASE2","title":"Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-10","conditions":"Chronic Renal Failure, Anemia, Dialysis","enrollment":60},{"nctId":"NCT02403362","phase":"PHASE2","title":"Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-06","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":60},{"nctId":"NCT02366325","phase":"PHASE2","title":"Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-07","conditions":"Chronic Renal Failure, Anemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HS-20039","EPO-018B"],"phase":"phase_3","status":"active","brandName":"pegol-Sihematide","genericName":"pegol-Sihematide","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production. Used for Anemia associated with chronic kidney disease (CKD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}